EscharEx - MediWound

Drug Profile

EscharEx - MediWound

Alternative Names: EscharEx

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator MediWound
  • Class Enzymes; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leg ulcer; Wounds

Most Recent Events

  • 31 Jan 2017 Final efficacy data from a phase II trial in Wounds released by MediWound
  • 02 Feb 2016 Top-line efficacy data from a phase II trial in Wounds released by MediWound
  • 01 Sep 2015 MediWound completes enrolment in a phase II trial for Leg ulcer and Wounds in Hungry and Israel (NCT02020746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top